Czajkowski, Max
Kaemmerer, Daniel
Sänger, Jörg
Sauter, Guido
Wirtz, Ralph M.
Schulz, Stefan
Lupp, Amelie
Funding for this research was provided by:
Universitätsklinikum Jena
Article History
Received: 20 May 2022
Accepted: 30 June 2022
First Online: 7 July 2022
Declarations
:
: All procedures performed in this study involving human participants were in accordance with the 1964 Helsinki declaration and its later amendments. Permission was gained from the local ethics committee (Ethikkommission der Landesärztekammer Thüringen) for this retrospective analysis. Informed consent for the use of tissue samples for scientific purposes was obtained from all individual participants included in the study when entering the Theranostic Research Center, Zentralklinik Bad Berka, Bad Berka, Germany, and the Department of General, Visceral and Vascular Surgery, Jena University Hospital, Jena, Germany. All data were analysed anonymously.
: Not applicable.
: Daniel Kaemmerer received support for travelling to meetings by the companies IPSEN and PFIZER. Ralph M. Wirtz is the CEO and CSO of STRATIFYER Molecular Pathology GmbH, Cologne, Germany, and declares no competing interests. Stefan Schulz is the founder and scientific advisor of 7TM Antibodies GmbH, Jena, Germany, and declares no competing non-financial interests but competing financial interests. All other authors declare that there is no conflict of interest that could be perceived as prejudicing the impartiality of the research reported.